Voyager Therapeutics (VYGR) Income from Continuing Operations (2014 - 2026)
Voyager Therapeutics (VYGR) reported Income from Continuing Operations of 27937000.0 for Q1 2026, up 9.94% on a YoY basis from 25410751.41 in Q1 2025, and down 1.86% sequentially from 27426000.0 in Q4 2025.
Voyager Therapeutics (VYGR) Income from Continuing Operations (2014 - 2026) Analysis & Trends
Voyager Therapeutics (VYGR) has 13 years of Income from Continuing Operations data on file, last reported at 27937000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 9.94% year-over-year to 27937000.0; the trailing twelve-month figure through Mar 2026 stood at 116637000.0 (down 38.52% YoY), and the FY2025 full-year result was 119721000.0, down 85.58% from the prior year.
- Income from Continuing Operations fell to 27937000.0 in Q1 2026, from 27426000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 124044000.0 in Q1 2023 to a low of 33997000.0 in Q4 2024.
- A 5-year average of 7349294.12 and a median of 22208000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Peak annual rise in Income from Continuing Operations reached 681.85% in 2023, while the deepest fall reached 246.96% in 2023.
- Tracing VYGR's Income from Continuing Operations over 5 years: stood at 23610000.0 in 2022, then surged by 344.34% to 57689000.0 in 2023, then sank by 158.93% to 33997000.0 in 2024, then advanced by 19.33% to 27426000.0 in 2025, then slipped by 1.86% to 27937000.0 in 2026.
- Business Quant data shows VYGR's Income from Continuing Operations at 27937000.0 in Q1 2026, 27426000.0 in Q4 2025, and 27892000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Voyager Therapeutics | 184.74 Mn | 43.26 Mn | - | -27.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -27.94 Mn |
| Dec 31, 2025 | -27.43 Mn |
| Sep 30, 2025 | -27.89 Mn |
| Jun 30, 2025 | -33.38 Mn |
| Mar 31, 2025 | -31.02 Mn |
| Dec 31, 2024 | -34.00 Mn |
| Sep 30, 2024 | -9.04 Mn |
| Jun 30, 2024 | -10.14 Mn |
| Mar 31, 2024 | -11.33 Mn |
| Dec 31, 2023 | 57.69 Mn |
| Sep 30, 2023 | -25.90 Mn |
| Jun 30, 2023 | -22.21 Mn |
| Mar 31, 2023 | 124.04 Mn |
| Dec 31, 2022 | -23.61 Mn |
| Sep 30, 2022 | 17.62 Mn |
| Jun 30, 2022 | -19.09 Mn |
| Mar 31, 2022 | -21.32 Mn |
| Dec 31, 2021 | -101.87 Mn |
| Sep 30, 2021 | -83.74 Mn |
| Jun 30, 2021 | -42.71 Mn |